

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine: a cross-sectional patient survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-023667
Article Type:	Research
Date Submitted by the Author:	18-Apr-2018
Complete List of Authors:	MacKrill, Kate; University of Auckland Petrie, Keith; University of Auckland
Keywords:	generic medicine, drug switching, perceptions, nocebo, side effects

SCHOLARONE[™] Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

What is associated with increased side switching to a generic medicine: a cro	e effects and lower perceived efficacy follo ss-sectional patient survev
Kate MacKrill, Keith J Petrie	
University of Auckland, Private Bag 9201	9, New Zealand
Department of Psychological Medicine, L	Iniversity of Auckland, New Zealand.
Kate MacKrill, Graduate student, Departr Auckland	nent of Psychological Medicine, University o
Keith J Petrie, Professor, Department of	Psychological Medicine, University of Auckla
Word count: 3629	
Keywords: generic medicine; drug switch	ing; perceptions; nocebo; drug efficacy; side
Correspondence to: Professor Keith Petr	ie kj.petrie@auckland.ac.nz

ABSTRACT

OBJECTIVE

Following a switch from either a generic or branded antidepressant (venlafaxine) to a new generic we investigated the factors associated with a preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic drug.

DESIGN

A cross-sectional survey of patients switched to a new generic.

SETTING

Community

PARTICIPANTS

310 patients, comprising 205 originally on branded venlafaxine and 105 previously taking a generic version.

MAIN OUTCOME MEASURES

An online questionnaire assessing demographic factors, perceived sensitivity to medicines, trust in pharmaceutical agencies, sources of switch information, preference for branded medicine, new medicine perceptions, side effects and efficacy ratings.

RESULTS

Preference for branded medicine was significantly stronger in older patients, those taking branded venlafaxine and patients with a higher perceived sensitivity to medicine. In those switching from generic venlafaxine, higher reported side effects were associated with a lower perceived efficacy of the new generic. In those switching from branded venlafaxine, greater side effect reporting was associated with older age, female gender, lower education, time on previous medication and lower perceived efficacy of the new generic. The significant predictors of efficacy ratings of the new generic in both groups were trust in pharmaceutical agencies and the number of side effects.

CONCLUSIONS

In patients switching from a branded medicine and those already taking a generic, different demographic and psychological factors are associated with preference for branded medicine,

BMJ Open

side effect reporting and perceived efficacy of the new drug. When switching to new generic there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust through an explanation of equivalence testing and monitoring could impact on efficacy beliefs, reduce side effects and later non-adherence following a generic switch.

ARTICLE SUMMARY

Strengths and limitations of the study

- The study examined both patients on a branded-originator as well as those already on a generic switched to a new generic medicine.
- While previous research has used placebo treatments and non-patient participants, our study examined preferences and perceptions in a patient sample that had recently undergone a generic switch in antidepressant medication.
- Our study is limited by the fact that patients were not randomly sampled and whether respondents were actually taking venlafaxine could not be independently corroborated.

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Generic medicines present a cost-effective option for health funders, as they provide the same therapeutic effect as branded medicine, but at a much more affordable price. While generic drugs are now widely used, a significant proportion of the general public, doctors and pharmacists report negative perceptions of generics, in terms of their effectiveness, safety and likelihood to cause side effects.[1] Many patients believe that generic drugs are not suitable for treating serious conditions[2] and there seems greater reluctance to accept generics in patients already established on branded antidepressants compared to other types of medicines.[3]

Negative perceptions of generics can lead to an increase in the nocebo effect following switching from a branded to a generic alternative with greater complaints of side effects and beliefs that the new medication is less effective.[4] These perceptions can cause increased adverse event reporting, drug refusal and non-adherence when patients are switched from a branded to a generic medicine.[5-7] Beliefs that the drug is less effective or causing side effects can also result in a significant number of patients switching back to the branded medication, resulting in less cost savings for the health system.[8]

There has been little research on the factors associated with a nocebo response following a switch to generic medicine. Previous research suggests patients who have high perceived sensitivity to medicine may be more reluctant to change to a generic and more likely to report side effects.[9] Trust in pharmaceutical agencies such as drug companies and the government organisations regulating drugs also seem to be important factors in generic acceptance.[10] A recent study investigating the attribution of symptoms to a placebo described as "a well-known tablet" found that perceived sensitivity to medicine increased the odds of attributing symptoms to the placebo tablet, while trust in medicines and pharmaceutical companies decreased the likelihood of attributing symptoms.[11]

In 2017, the Pharmaceutical Management Agency (Pharmac), the New Zealand government agency responsible for subsidising medicines, changed the funded version of the antidepressant venlafaxine. Over the course of 2017, 45,000 New Zealanders prescribed

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

either Efexor XR (the branded originator) or Arrow-Venlafaxine XR (a generic version) were switched to a new generic, Enlafax XR. From the outset of the venlafaxine brand switch, some patients reported side effects from the new generic, such as nausea, fatigue, headaches, suicidal thoughts and stated that the drug was not as effective as their previous branded version. Media stories following the switch to generic venlafaxine reflected patient concerns, with article headlines such as "Patients say generic Pharmac-funded version of antidepressant venlafaxine left them depressed, anxious"[12] and "Anti-depressant swap: Sufferers claim generic drug is harming their condition".[13] This drug switch allowed the opportunity to examine differences between patients switched from an originator brand as well as generic venlafaxine to a new generic version of the antidepressant. The aim of the study was to investigate how both branded and generic groups viewed generic drugs and what factors influenced a preference for branded medicines. We also investigated what factors were associated with side effect reporting following the switch and patients' efficacy ratings of the new generic drug.

METHOD

Participants and procedure

Visitors to the <u>venlafaxine brand change page</u> on the Pharmac website were invited to complete an online questionnaire about their perceptions and experiences of the venlafaxine brand change. To be eligible to participate, respondents had to be 16 years of age or older and currently taking any brand of venlafaxine medication. A link to the survey was provided on the same webpage and was live from 6 March 2017 to 29 October 2017. The survey was anonymous and confidential, with IP addresses and geo-location data from individual responses not recorded. In total, 413 people accessed the survey, however, 103 respondents were excluded: 85 did not complete the survey, nine did not meet the inclusion criteria and a further nine participants did not know their original brand of venlafaxine. This resulted in a final sample of 310 participants.

Measures

Demographic information

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 6 of 19

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Participants completed information on age, gender, relationship status, employment status, highest level of education completed and ethnicity.

Venlafaxine brand information, efficacy ratings and medication preference Introductory survey questions collected information on participants' old venlafaxine prescription, specifically the medication brand, time on drug and how participants found out about the brand switch. Participants' perceived efficacy of their old brand and the new generic was assessed using an 11-point scale from 0 "Does not work well" to 10 "Works extremely well". Participants were asked to consider if given the choice to take a branded or generic version of a prescribed medicine with no difference in cost, which medicine would they prefer to take? Answers were scored "branded version", "generic version" or "no preference". They were also asked to specify, of branded versus generic medicines, which did they expect to be more effective, safe and have fewer side effects. Answers were scored "branded version", "generic version" or "no difference". Participants were also asked: "how often do you look up medication information on the Internet?" assessed using an 11-point scale from 0 "Never" to 10 "Always".

Trust in pharmaceutical agencies

Participants were asked to rate how much they trusted brand switch information from pharmacists, PHARMAC, Medsafe and pharmaceutical companies on an 11-point scale from 0 "Do not trust" to 10 "Completely trust". Participants' scores for these items were summed to create an overall score of trust in pharmaceutical agencies, which had an acceptable Cronbach's alpha (α = .79).

Side effects

Participants were given a list of 15 frequently reported symptoms (e.g., headache, dizziness, chest pain, nausea, abdominal pain[14]) and were asked to indicate whether they had experienced any from the new generic venlafaxine within the past week. Answers were scored "yes", "maybe" or "no". The number of side effects experienced (both yes and maybe) was summed to create a total side effect score.

Perceived sensitivity to medicines

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The perceived sensitivity to medicines scale[15] was used to assess participants' self-rated reaction to medicines. The scale consists of five items rated on a 5-point scale from 1 "Strongly Disagree" to 5 "Strongly Agree", an example being "My body overacts to medicines". The five items were summed to create a total sensitivity score ranging from 5 to 25, with higher scores indicating a greater perceived sensitivity to the adverse effect of medicines.

Statistical analyses

Analyses were performed using IBSM SPSS 24. To ascertain what factors influence people's general medicine preferences, a logistic regression was conducted with medication preference converted to a binary outcome variable of generic or no preference (0) versus a preference for branded medication (1). The predictors in this model were age, gender, education level (dichotomised and dummy coded as university degree 1 or lower 0), ethnicity (NZ European 1 or other 0, pre-switch medication type (brand 1 or generic 0) time on previous venlafaxine brand, participants' perceived efficacy of their old brand, perceived efficacy of the new generic, perceived sensitivity to medicines score, pharmaceutical trust score and the degree to which participants look up medicine information on the internet.

In further analyses, the total sample was separated into two groups: the participants who switched from branded venlafaxine to the new generic and those who switched from the old generic to the new version. Independent sample t-tests and chi-square tests were conducted to investigate whether there were any differences between the brand and generic switch groups on demographic variables, beliefs about the efficacy, safety and side effects of branded and generic medicines, efficacy ratings of the new generic venlafaxine and side effect reports. To investigate what factors were associated with the two groups' efficacy ratings of the new generic, a multiple linear regression was conducted for each group using participants' efficacy rating of the new generic as the outcome variable. The predictor variables used in these analyses were the same variables used in the analysis of medication preferences, except with the removal of pre-switch medication type and new generic efficacy rating and the inclusion of the number of side effects reported. To investigate the factors

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

associated with greater side effect reporting in the two groups, multiple linear regressions were conducted with the side effect score as the outcome variable. The predictor variables used in these models were the same as medication preferences except with pre-switch medication type removed. An alpha level of .05 was used for all analyses.

RESULTS

The sample was predominantly female n = 246 (79.4%) with a mean age of 45 years (*SD* = 13.50). The majority of the sample identified as New Zealand or other European n = 275 (88.7%), 21 (6.8%) as Māori and smaller proportions identifying as Asian, Pacific Islander and other ethnicities. The demographic breakdown of the sample is similar to the total population of venlafaxine users in New Zealand. Two hundred and five people were previously on branded venlafaxine and 105 were taking a generic. There were no significant differences between the two switch groups on demographic variables (see table 1).

The majority of the sample, n = 228 (73.5%), found out about the venlafaxine brand switch through a pharmacist, while 45 participants (14.5%) said they were not directly told about the switch and only found out after noticing a change in their tablets and 12 people (3.9%) were informed of the brand switch by their doctor. The remaining proportion either found out through the Pharmac website, social media or news media, or friends and family. However, when participants were asked how they would have preferred to have found out about the brand switch, 173 (55.8%) said through their doctor, 86 (27.7%) by a pharmacist and 36 (11.6%) from Pharmac directly.

Page 9 of 19

BMJ Open

 Table 1
 Demographics characteristics for the population of venlafaxine users and comparison between branded and generic switch study samples

	Population (n = 49,175)	Brand Sample (n = 205)	Generic Sample (n = 105)		
Variable	n (%)	n (%)	n (%)	t/χ ²	р
Age (mean, SD)	-	45.0 (13.16)	44.3 (14.18)	0.38	.703
Age group				5.44	.364
> 19 years	1,155 (2.3)	0	1 (1.0)		
20-29 years	7,309 (14.9)	27 (13.2)	20 (19.0)		
30-39 years	8,202 (16.7)	50 (24.4)	20 (19.0)		
40-49 years	10,899 (22.2)	50(24.4)	21 (20.0)		
50-69 years	16,677 (33.9)	51 (24.9)	26 (24.8)		
< 70 years	4,933 (10.0)	27 (13.2)	17 (16.2)		
Gender				0.70	.40
Male	17,478 (35.5)	42 (20.7)	17 (16.7)		
Female	31,695 (64.5)	161 (79.3)	85 (83.3)		
Ethnicity				0.22	.89
European	42,944 (87.3)	184 (90.6)	91 (89.2)		
Māori	4,210 (8.6)	13 (6.4)	8 (7.8)		
Other	2,021 (4.1)	6 (3.0)	3 (2.9)		
Education level				3.26	.19
Secondary school or below	N	44 (22.0)	33 (31.4)		
Diploma/Trade certificate		68 (34.0)	32 (30.5)		
University degree		88 (44.0)	40 (38.1)		
Relationship status				5.83	.12
Married, civil union, cohabiting		124 (61.7)	53 (51.5)		
Single		48 (23.9)	32 (31.1)		
Divorced, separated		25 (12.4)	18 (17.5)		
Widow, widower		4 (2.0)	0		

 t/χ^2 analyses conducted between the brand sample and generic sample.

Population data obtained from Pharmac.

Preference for branded or generic medicine

One hundred and eighty participants (58.1%) reported a greater preference for branded medicines overall while 130 (41.9%) preferred generics or had no preference. Compared to those previously taking a generic, a greater proportion of those originally taking the branded

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

venlafaxine considered branded medicines to be safer, more effective and have fewer side effects than generics (Figure 1). Those prescribed generics were more likely to perceive branded and generic medicines as being equivalent in safety, efficacy and the number of side effects.

(Figure 1)

The analysis of factors influencing people's medicine preferences was significant, $\chi^2(12) = 44.74$, p < .001, Nagelkerke $R^2 = .20$. The significant factors associated with medicine preference were participants' age, pre-switch medication type and perceived sensitivity to medicines. The results indicate that an older age, originally being on the branded venlafaxine medication and a greater perceived sensitivity to medicines is associated with a greater preference for branded medicines overall (Table 2).

Table 2 Factors associated with a preference for branded medicines

Variable	В	Wald	OR	р	95% CI for OR
Age	0.04	10.66	1.04	.001	1.01, 1.05
Gender	-0.16	0.21	0.86	.647	0.44, 1.67
Education level	-0.23	0.68	0.80	.411	0.46, 1.37
Ethnicity	0.33	0.72	1.40	.396	0.65, 3.01
Pre-switch medication type	0.71	5.55	2.02	.019	1.13, 3.64
Time on previous brand	0.00	0.00	1.00	.961	0.86, 1.18
Perceived efficacy of old brand	0.11	2.97	1.11	.085	0.99, 1.25
Perceived efficacy of new generic	0.00	0.01	1.00	.940	0.92, 1.10
Perceived sensitivity to medicines	0.11	14.17	1.12	<.001	1.06, 1.19
Trust in pharmaceutical agencies	-0.02	1.60	0.98	.206	0.95, 1.01
Look up medicine information on internet	0.03	0.34	1.03	.560	0.93, 1.14

Efficacy ratings of the new generic

Both brand and generic switchers rated the efficacy of their old medication very highly (brand switchers M = 8.46 out of 10, SD = 2.52; generic switchers M = 8.43, SD = 2.16). For the new generic, there were no differences between brand switchers (M = 3.04, SD = 2.97) and generic switchers (M = 3.46, SD = 3.09) in efficacy ratings, t(299) = -1.17, p = .244, 95% CI - 1.14 to 0.29. The factors associated with efficacy ratings in the brand and generic switch

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

groups were investigated. The regression model was significant for the brand switch group, F(10, 172) = 3.72, p < .001, $R^2 = .18$, and the generic switch group, F(10, 84) = 5.07, p < .001, $R^2 = .38$. For both the brand and generic switch groups, the only variables that were significant predictors of new generic efficacy ratings was the pharmaceutical trust score and number of side effects reported (see table 3). Regardless of whether participants were switching from a branded medicine or a generic, a greater degree of trust in pharmaceutical agencies and fewer side effects reported were associated with a greater perceived efficacy of the new generic venlafaxine.

Table 3 Factors associated with the efficacy ratings of the new generic medicine for brand switchers and generic switchers

		Bra	nd Switch	ers		Gene	eric Switch	ners
Variable	В	β	p	95% CI for B	В	β	p	95% CI for B
Age	-0.01	03	.656	-0.04, 0.03	0.02	.07	.457	-0.03, 0.06
Gender	0.53	.07	.304	-0.48, 1.54	-0.98	12	.187	-2.44, 0.48
Education level	-0.78	13	.079	-1.66, 0.09	-0.58	09	.339	-1.77, 0.62
Ethnicity	-1.16	13	.086	-2.49, 0.17	0.03	.00	.966	-1.44, 1.51
Time on previous brand	-0.16	09	.245	-0.42, 0.11	-0.07	04	.677	-0.38, 0.25
Perceived efficacy of old brand	0.16	.13	.083	-0.02, 0.34	0.02	01	.891	-0.25, 0.29
Perceived sensitivity to medicines	0.02	.03	.679	-0.07, 0.10	-0.03	04	.682	-0.15, 0.10
Trust in pharmaceutical agencies	0.09	.26	<.001	0.04, 0.13	0.18	.45	<.001	0.11, 0.24
Look up medicine information on internet	-0.02	01	.854	-0.18, 0.15	-0.01	01	.959	-0.22, 0.21
Number of side effects	-0.17	235	.002	-0.28, -0.07	-0.27	33	<.001	-0.42, -0.13

Side effect reports from the new generic

There was no significant difference in the brand group (M = 4.43, SD = 4.07) and generic group (M = 4.85, SD = 3.91) in reported side effects following the switch to the new generic, t(308) = -0.86, p = .392, 95% CI -1.36 to 0.54. An analysis of the factors associated with greater side effect reporting for brand switchers and generic switchers was conducted and is summarised in table 4. The regression model of the brand switchers was significant, *F*(10, 172) = 3.61, p < .001, $R^2 = .17$. Age, gender, education level, duration of time on the old brand and perceived efficacy of the new generic were significantly associated with side effect reporting. The analysis shows that brand switchers who were older, female, had an

education level below a university degree, had taken Efexor for a longer period of time and had a lower perceived efficacy of the new generic reported a greater number of side effects from the new generic medication.

The regression model for the generic switchers was also significant F(10, 84) = 2.13, p = .031, $R^2 = .20$. However, the only significant predictor of side effects for this group was perceived efficacy of the new generic. Generic switchers who had a lower perceived efficacy of the new generic reported more side effects following the switch to the new generic.

Table 4 Factors associated with side effect reporting for brand switchers and generic switchers

	4	Bran	d Switche	rs		Generi	c Switche	ers
Variable	В	β	p	95% CI for B	В	β	р	95% CI for B
Age	0.06	.18	.017	0.01, 0.10	0.01	.04	.671	-0.05, 0.07
Gender	1.41	.14	.047	0.02, 2.79	-0.96	10	.347	-2.99, 1.06
Education level	-1.61	20	.008	-2.81, -0.42	-1.04	13	.210	-2.68, 0.60
Ethnicity	-0.39	03	.680	-2.23, 1.46	-1.23	12	.229	-3.24, 0.79
Time on previous brand	-0.50	20	.007	-0.86, -0.14	0.07	.03	.766	-0.37, 0.50
Perceived efficacy of old brand	0.21	.12	.102	-0.04, 0.46	0.13	.08	.461	-0.24, 0.51
Perceived efficacy of new generic	-0.33	24	.002	-0.53, -0.13	-0.52	42	<.001	-0.79, -0.24
Perceived sensitivity to medicines	-0.04	05	.486	-0.16, 0.08	0.03	.04	.718	-0.14, 0.20
Trust in pharmaceutical agencies	-0.01	02	.760	-0.07, 0.06	0.06	.13	.245	-0.04, 0.17
Look up medicine information on internet	-0.05	03	.664	-0.28, 0.18	0.16	.12	.282	-0.13, 0.46

DISCUSSION

Key findings

In a sample of patients switched to a new generic version of venlafaxine the study found that preference for branded medication was associated with older age, being on the branded venlafaxine medication prior to the switch and a greater perceived sensitivity to medicines. A greater proportion of patients originally prescribed branded venlafaxine expected branded medicines to be more effective, safe and have fewer side effects than generics, compared to patients taking the generic who were more likely to perceive branded and generic medicines as equivalent. For both patient groups, those switching from the branded medication and those switching from a generic, a greater degree of trust in pharmaceutical agencies and less side effects reported were associated with a higher perceived efficacy of the new generic

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

venlafaxine. For those switching from the branded venlafaxine, being older, female, having a lower education level, being on the branded drug for a longer time and having a lower perceived efficacy of the new generic was associated with reporting a greater number of side effects from the new generic medication. For those patients already on a generic, only a lower perceived efficacy of the new drug was associated with side effect reporting.

Implications

Switches from originator branded medicines to their generic counterparts provide an economic choice for health funders by enabling more patients to be treated through costsavings. Negative perceptions of generics can cause increased side effects and perceptions of lower efficacy, which may result in non-adherence and low persistence with the new drug and reduce the potential economic benefits of a switch. This study shows that trust in pharmaceutical agencies, including drug companies and regulators, is a key factor in patients' beliefs in the efficacy of the new generic medicine.

Another important finding of the study is the close reciprocal relationship between perceived drug efficacy and reported side effects. The presence of increased side effects are associated with a perception that the drug does not work as well and conversely, this low efficacy beliefs are associated with greater reports of side effects. This is consistent with a recent study that showed when side effects are modelled by another person receiving the same medication (study confederate), this can influence not only reported side effects in the individual viewing the person but also reduce the effectiveness of the drug.[16]

The study also highlights the fact that patients who switch from a branded medicine and those who switch from a generic are likely to have different concerns. Patients already on a generic medicine tend to have a more favourable perception of generics compared to those taking a branded medicine and the factors that influence side effect reports following a medicine brand switch are different for brand switchers compared to generic switchers. People switching from branded medicines are likely to have more difficulties and interventions focused on building trust in pharmaceutical agencies around the switch are likely to have positive effects in influencing the perceived efficacy of the new drug and

subsequent side effects. This could include explaining the level of testing required to establish drug equivalency and the monitoring of that does occur by drug agencies.

Strengths and limitations

One of the strengths of the study was that it included patients who were switched from branded originator medication as well as patients on a generic. To our knowledge this is the first time a study has looked at these groups in the same switch to a generic to examine factors related to side effect reporting and efficacy perceptions. Previous research investigating perceptions and responses to medicine change has previously used placebo tablets and non-patient participants.[4,17] The fact that the sample was recruited from the Pharmac venlafaxine brand change webpage means these patients are likely to be more typical of patients who have concern and difficulties managing a generic switch. A weakness of the study was that patients were not randomly sampled and whether respondents were actually taking venlafaxine could not be independently corroborated.

Conclusions

These results suggest in a switch to a generic drug different factors are associated with preference for branded medicine, side effect reporting and perceived efficacy of the new drug in patients switching from a branded medicine and those already taking a generic. When switching to new generic there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust through an explanation of equivalence testing and monitoring could impact on efficacy beliefs, reduce nocebo effects and later non-adherence following a generic switch.

Acknowledgements

Janet Mackay from Pharmac for help with establishing the survey and demographic breakdown of venlafaxine users.

Author contributions KM and KJP designed the study, planned the data analysis, interpreted the results and drafted and revised the manuscript. KM collected the data and performed the data analyses. KP is guarantor.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: We have read and understood BMJ policy on declaration of interest and declare the following: KM declares no conflict of interest. KP has previously received research funding from Pharmac, the New Zealand Government's Pharmaceutical Management Agency.

Licence. The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and to exploit all subsidiary rights, as set out in our licence (bmj.com/advice/copyright.shtml).

Data sharing statement No additional data available.

Patient consent: Obtained

Ethics approval University of Auckland Human Participants Ethics Committee (ref. 018622).

REFERENCES

1. Colgan S, Faasse K, Martin LR, *et al.* Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. *BMJ Open* 2015;5:e008915.

2. Figueiras MJ, Cortes MA, Marcelino D, *et al.* Lay views about medicines: the influence of the illness label for the use of generic versus brand. *Psychol Health* 2010;25:1121-1128.

3. Pechlivanoglou P, Jan van der Veen W, Bos JH, *et al.* Analyzing generic and branded substitution patterns in the Netherlands using prescription data. *BMC Health Serv Res* 2011;11:89-98.

4. Faasse K, Cundy T, Gamble G, *et al*. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. *Psychosom Med* 2013;75:90-96.

5. Rathe J, Andersen M, Jarbøl DE, *et al.* Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study. *PLoS One* 2015;10:e0119688.

6. Weissenfeld J, Stock S, Lüngen M, *et al.* The nocebo effect: a reason for patients' nonadherence to generic substitution? *Die Pharmazie-An International Journal of Pharmaceutical Sciences* 2010;65:451-456.

7. Zeidan B, Anderson K, Peiris L, *et al.* The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients. *The Breast* 2016;29:62-67.

8 Desai RJ, Sarpatwari A, Dejene S, *et al.* Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. *BMJ* 2018;361:k1180.

9. Faasse K, Grey A, Horne R, *et al.* High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information seeking about medication. *Pharmacoepidemiol Drug Saf* 2015;24:592-599.

10. Balasopoulos T, Charonis A, Athanasakis K, *et al.* Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions. *Health Policy* 2017;121:265-272.

11. Webster RK, Weinman J, Rubin GJ. Medicine related beliefs predict attribution of symptoms to a sham medicine: a prospective study. *Br J Health Psychol* 2018.

12. Henry D. Patients say generic Pharmac-funded version of antidepressant venlafaxine left them depressed, anxious. *The New Zealand Herald* 2018 Feb. http://www.nzherald.co.nz/ (accessed 17 Apr 2018).

13. Maude S. Anti-depressant swap: Sufferers claim generic drug is harming their condition. *Stuff* 2018 Feb. https://www.stuff.co.nz (accessed 17 Apr 2018).

14. Petrie KJ, Faasse K, Crichton F, *et al.* How common are symptoms? Evidence from a New Zealand national telephone survey. *BMJ Open* 2014;4:005374.

15. Horne R, Faasse K, Cooper V, *et al*. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. *Br J Health Psychol* 2013;18:18-30.

16. Faasse K, Grey A, Jordan R, *et al.* Seeing is believing: impact of social modelling on placebo and nocebo responding. *Health Psychol* 2015;34:880-885.

17. Faasse K, Martin LR, Grey A, *et al.* Impact of brand or generic labeling on medication effectiveness and side effects. *Health Psychol* 2016;35:187-190.

to beer teries only

Figure 1 Comparison of the people on branded venlafaxine and those on generic venlafaxine in their beliefs about the efficacy, safety and side effects of branded and generic



BMJ Open

What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-023667.R1
Article Type:	Research
Date Submitted by the Author:	12-Jul-2018
Complete List of Authors:	MacKrill, Kate; University of Auckland Petrie, Keith; University of Auckland
Primary Subject Heading :	Pharmacology and therapeutics
Secondary Subject Heading:	Communication, Health services research, Pharmacology and therapeutics
Keywords:	generic medicine, drug switching, perceptions, nocebo, side effects



BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

What is associated with increased	side effects and lower perceived efficacy follo
switching to a generic medicine? /	A New Zealand cross-sectional patient survey
Kate MacKrill, Keith J Petrie	
University of Auckland, Private Bag 9	2019, New Zealand
Department of Psychological Medicin	e, University of Auckland, New Zealand.
Kate MacKrill, Graduate student, Dep	partment of Psychological Medicine, University of
Auckland	
Keith J Petrie, Professor, Departmen	t of Psychological Medicine, University of Aucklan
Word count: 3629	
Keywords: generic medicine; drug sv	vitching; perceptions; nocebo; drug efficacy; side e
Correspondence to: Professor Keith	Petrie kj.petrie@auckland.ac.nz

ABSTRACT

OBJECTIVE

Following a switch from either a generic or branded antidepressant (venlafaxine) to a new generic we investigated the factors associated with a preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic drug.

DESIGN

A cross-sectional survey of patients switched to a new generic.

SETTING

Patients accessing venlafaxine information online from the New Zealand government pharmaceuticals funding website.

PARTICIPANTS

310 patients, comprising 205 originally on branded venlafaxine and 105 previously taking a generic version.

MAIN OUTCOME MEASURES

An online questionnaire assessing demographic factors, perceived sensitivity to medicines, trust in pharmaceutical agencies, sources of switch information, preference for branded medicine, new medicine perceptions, side effects and efficacy ratings.

RESULTS

Preference for branded medicine was significantly stronger in older patients (OR=1.04, 95% CI 1.01 to 1.05), those taking branded venlafaxine (OR=2.02, 95% CI 1.13 to 3.64) and patients with a higher perceived sensitivity to medicine (OR=1.23, 95% CI 1.06 to 1.19). Different factors predicted side effects in those switching from a branded and those switching from a generic venlafaxine. Trust in pharmaceutical agencies and the number of side effects were significant predictors of efficacy ratings of the new generic in both patients switching from a branded and those switching from a generic version of venlafaxine.

CONCLUSIONS

In patients switching from a branded medicine and those already taking a generic, different demographic and psychological factors are associated with preference for branded medicine,

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

side effect reporting and perceived efficacy of the new drug. When switching to new generic there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust could reduce the nocebo response following a generic switch.

ARTICLE SUMMARY

Strengths and limitations of the study

- The study examined both patients on a branded-originator as well as those already on a generic switched to a new generic medicine.
- While previous research has used placebo treatments and non-patient participants, our study examined preferences and perceptions in a patient sample that had recently undergone a generic switch in antidepressant medication.
- Our study is limited by the fact that patients were not randomly sampled and whether respondents were actually taking venlafaxine could not be independently corroborated.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Generic medicines present a cost-effective option for health funders, as they provide the same therapeutic effect as branded medicine, but at a much more affordable price. While generic drugs are now widely used, a significant proportion of the general public, doctors and pharmacists report negative perceptions of generics, in terms of their effectiveness, safety and likelihood to cause side effects.[1] Many patients believe that generic drugs are not suitable for treating serious conditions[2] and there seems greater reluctance to accept generics in patients already established on branded antidepressants compared to other types of medicines.[3]

Negative perceptions of generics can lead to an increase in the nocebo effect following switching from a branded to a generic alternative with greater complaints of side effects and beliefs that the new medication is less effective.[4] These perceptions can cause increased adverse event reporting, drug refusal and non-adherence when patients are switched from a branded to a generic medicine.[5-7] Beliefs that the drug is less effective or causing side effects can also result in a significant number of patients switching back to the branded medication, resulting in less cost savings for the health system.[8]

There has been little research on the factors associated with a nocebo response following a switch to generic medicine. Previous research suggests patients who have high perceived sensitivity to medicine may be more reluctant to change to a generic and more likely to report side effects.[9] Trust in pharmaceutical agencies such as drug companies and the government organisations regulating drugs also seem to be important factors in generic acceptance.[10] A recent study investigating the attribution of symptoms to a placebo described as "a well-known tablet" found that perceived sensitivity to medicine increased the odds of attributing symptoms to the placebo tablet, while trust in medicines and pharmaceutical companies decreased the likelihood of attributing symptoms.[11]

In 2017, the Pharmaceutical Management Agency (Pharmac), the New Zealand government agency responsible for subsidising medicines, changed the funded version of the antidepressant venlafaxine. Over the course of 2017, 45,000 New Zealanders prescribed

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

either Efexor XR (the branded originator) or Arrow-Venlafaxine XR (a generic version) were switched to a new generic, Enlafax XR. From the outset of the venlafaxine brand switch, some patients reported side effects from the new generic, such as nausea, fatigue, headaches, suicidal thoughts and stated that the drug was not as effective as their previous branded version. Media stories following the switch to generic venlafaxine reflected patient concerns, with article headlines such as "Patients say generic Pharmac-funded version of antidepressant venlafaxine left them depressed, anxious"[12] and "Anti-depressant swap: Sufferers claim generic drug is harming their condition".[13] This drug switch allowed the opportunity to examine differences between patients switched from an originator brand as well as generic venlafaxine to a new generic version of the antidepressant. The aim of the study was to investigate how both branded and generic groups viewed generic drugs and what factors influenced a preference for branded medicines. We also investigated what factors were associated with side effect reporting following the switch and patients' efficacy ratings of the new generic drug.

METHOD

Participants and procedure

Visitors to the <u>venlafaxine brand change page</u> on the Pharmac website were invited to complete an online questionnaire about their perceptions and experiences of the venlafaxine brand change. To be eligible to participate, respondents had to be 16 years of age or older and currently taking any brand of venlafaxine medication. A link to the survey was provided on the same webpage and was live from 6 March 2017 to 29 October 2017. The survey was anonymous and confidential, with IP addresses and geo-location data from individual responses not recorded. As the survey was anonymous, completion and submission of the questionnaire implied informed consent to participate. This was stated on the participant information page, which respondents read before starting the questionnaire. The University of Auckland Human Participants Ethics Committee approved the study (ref. 018622).

Measures

Demographic information

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Participants completed information on age, gender, relationship status, employment status, highest level of education completed and ethnicity.

Venlafaxine brand information and efficacy ratings

Introductory survey questions collected information on participants' old venlafaxine prescription, specifically the medication brand, time on drug and how participants found out about the brand switch. Participants' perceived efficacy of their old brand and the new generic was assessed using an 11-point scale from 0 "Does not work well" to 10 "Works extremely well" which was developed for this study.

Medication preference

Participants were asked to consider if given the choice to take a branded or generic version of a prescribed medicine with no difference in cost, which medicine would they prefer to take? Answers were scored "branded version", "generic version" or "no preference". They were also asked to specify, of branded versus generic medicines, which did they expect to be more effective, safe and have fewer side effects. Answers were scored "branded version", "generic version" or "no difference". Participants were also asked: "how often do you look up medication information on the Internet?" assessed using an 11-point scale from 0 "Never" to 10 "Always". These items have been previously used in a large general population survey [9]. *Trust in pharmaceutical agencies*

Participants were asked to rate how much they trusted brand switch information from pharmacists, PHARMAC, Medsafe and pharmaceutical companies on an 11-point scale from 0 "Do not trust" to 10 "Completely trust". Participants' scores for these items which were developed for this study were summed to create an overall score of trust in pharmaceutical agencies, which had an acceptable Cronbach's alpha ($\alpha = .79$).

Side effects

Participants were given a list of 15 frequently reported symptoms (e.g., headache, dizziness, chest pain, nausea, abdominal pain[14]) and were asked to indicate whether they had experienced any from the new generic venlafaxine within the past week. Answers were

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

scored "yes", "maybe" or "no". The number of side effects experienced (both yes and maybe) was summed to create a total side effect score.

Perceived sensitivity to medicines

The perceived sensitivity to medicines scale[15] was used to assess participants' self-rated reaction to medicines. The scale consists of five items rated on a 5-point scale from 1 "Strongly Disagree" to 5 "Strongly Agree", an example being "My body overacts to medicines". The five items were summed to create a total sensitivity score ranging from 5 to 25, with higher scores indicating a greater perceived sensitivity to the adverse effect of medicines. The scale has shown acceptable reliability and validity in a general population sample[9] as well as in different patient groups[15,16].

Statistical analyses

Analyses were performed using IBSM SPSS 24. To ascertain what factors influenced a preference for branded medicines, a logistic regression was conducted with medication preference converted to a binary outcome variable of generic or no preference (0) versus a preference for branded medication (1). The predictors in this model were age, gender, education level (dichotomised and dummy coded as university degree 1 or lower 0), ethnicity (NZ European 1 or other 0, pre-switch medication type (brand 1 or generic 0) time on previous venlafaxine brand, participants' perceived efficacy of their old brand, perceived efficacy of the new generic, perceived sensitivity to medicines score, pharmaceutical trust score and the degree to which participants look up medicine information on the internet.

In further analyses, the total sample was separated into two groups: the participants who switched from branded venlafaxine to the new generic and those who switched from the old generic to the new version. Independent sample t-tests and chi-square tests were conducted to investigate whether there were any differences between the brand and generic switch groups on demographic variables, beliefs about the efficacy, safety and side effects of branded and generic medicines, efficacy ratings of the new generic venlafaxine and side effect reports. To investigate what factors were associated with the two groups' efficacy ratings of the new generic, a multiple linear regression was conducted for each group using

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

participants' efficacy rating of the new generic as the outcome variable. The predictor variables used in these analyses were the same variables used in the analysis of medication preferences, except with the removal of pre-switch medication type and new generic efficacy rating and the inclusion of the number of side effects reported. To investigate the factors associated with greater side effect reporting in the two groups, multiple linear regressions were conducted with the side effect score as the outcome variable. The predictor variables used in these models were the same as medication preferences except with pre-switch medication type removed. An alpha level of .05 was used for all analyses.

Patient and public involvement

Patients and the public were not involved in the development and conduct of this study.

RESULTS

In total, 413 people accessed the survey, however, 103 respondents were excluded: 85 did not complete the survey, nine did not meet the inclusion criteria and a further nine participants did not know their original brand of venlafaxine. This resulted in a final sample of 310 participants. The sample was predominantly female n = 246 (79.4%), with a mean age of 45 years (SD = 13.50). The majority of the sample identified as New Zealand or other European n = 275 (88.7%), 21 (6.8%) as Māori and smaller proportions identifying as Asian, Pacific Islander and other ethnicities. The demographic breakdown of the sample is similar to the total population of venlafaxine users in New Zealand, as shown in Table 1. Two hundred and five people were previously on branded venlafaxine and 105 were taking a generic. There were no significant differences between the two switch groups on demographic variables (Table 1).

The majority of the sample, n = 228 (73.5%), found out about the venlafaxine brand switch through a pharmacist, while 45 participants (14.5%) said they were not directly told about the switch and only found out after noticing a change in their tablets and 12 people (3.9%) were informed of the brand switch by their doctor. The remaining proportion either found out through the Pharmac website, social media or news media, or friends and family. However, when participants were asked how they would have preferred to have found out

about the brand switch, 173 (55.8%) said through their doctor, 86 (27.7%) by a pharmacist

and 36 (11.6%) from Pharmac directly.

Table 1 Demographics characteristics for the population of venlafaxine users and comparison between branded and generic switch study samples

	Population (n = 49.175)	Brand Sample (n = 205)	Generic Sample (n = 105)		
Variable	n (%)	n (%)	n (%)	t/χ ²	р
Age (mean, SD)	-	45.0 (13.16)	44.3 (14.18)	0.38	.703
Age group				5.44	.364
> 19 years	1,155 (2.3)	0	1 (1.0)		
20-29 years	7,309 (14.9)	27 (13.2)	20 (19.0)		
30-39 years	8,202 (16.7)	50 (24.4)	20 (19.0)		
40-49 years	10,899 (22.2)	50(24.4)	21 (20.0)		
50-69 years	16,677 (33.9)	51 (24.9)	26 (24.8)		
< 70 years	4,933 (10.0)	27 (13.2)	17 (16.2)		
Gender				0.70	.401
Male	17,478 (35.5)	42 (20.7)	17 (16.7)		
Female	31,695 (64.5)	161 (79.3)	85 (83.3)		
Ethnicity				0.22	.896
European	42,944 (87.3)	184 (90.6)	91 (89.2)		
Māori	4,210 (8.6)	13 (6.4)	8 (7.8)		
Other	2,021 (4.1)	6 (3.0)	3 (2.9)		
Education level				3.26	.196
Secondary school or below		44 (22.0)	33 (31.4)		
Diploma/Trade certificate		68 (34.0)	32 (30.5)		
University degree		88 (44.0)	40 (38.1)		
Relationship status				5.83	.120
Married, civil union, cohabiting		124 (61.7)	53 (51.5)		
Single		48 (23.9)	32 (31.1)		
Divorced, separated		25 (12.4)	18 (17.5)		
Widow, widower		4 (2.0)	0		

 t/χ^2 analyses conducted between the brand sample and generic sample.

Population data obtained from Pharmac.

Preference for branded or generic medicine

One hundred and eighty participants (58.1%) reported a greater preference for branded medicines overall while 130 (41.9%) preferred generics or had no preference. Compared to the people previously taking a generic, a greater proportion of those originally taking the branded venlafaxine considered branded medicines to be safer, more effective and have fewer side effects than generics (Figure 1). Those prescribed generics were more likely to perceive branded and generic medicines as being equivalent in safety, efficacy and the number of side effects.

(Figure 1)

The analysis of factors influencing people's medicine preferences was significant, $\chi^2(12) = 44.74$, p < .001, Nagelkerke $R^2 = .20$. The significant factors associated with medicine preference were participants' age, pre-switch medication type and perceived sensitivity to medicines. The results indicate that an older age, originally being on the branded venlafaxine medication and a greater perceived sensitivity to medicines is associated with a greater preference for branded medicines overall (Table 2).

Table 2 Factors associated with a preference for branded medicines

Variable	В	Wald	OR	р	95% CI for OR
Age	0.04	10.66	1.04	.001	1.01, 1.05
Gender	-0.16	0.21	0.86	.647	0.44, 1.67
Education level	-0.23	0.68	0.80	.411	0.46, 1.37
Ethnicity	0.33	0.72	1.40 <	.396	0.65, 3.01
Pre-switch medication type	0.71	5.55	2.02	.019	1.13, 3.64
Time on previous brand	0.00	0.00	1.00	.961	0.86, 1.18
Perceived efficacy of old brand	0.11	2.97	1.11	.085	0.99, 1.25
Perceived efficacy of new generic	0.00	0.01	1.00	.940	0.92, 1.10
Perceived sensitivity to medicines	0.11	14.17	1.12	<.001	1.06, 1.19
Trust in pharmaceutical agencies	-0.02	1.60	0.98	.206	0.95, 1.01
Look up medicine information on internet	0.03	0.34	1.03	.560	0.93, 1.14

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Efficacy ratings	of the	new	generic
------------------	--------	-----	---------

Both brand and generic switchers rated the efficacy of their old medication very highly (brand switchers M = 8.46 out of 10, SD = 2.52; generic switchers M = 8.43, SD = 2.16). For the new generic, there were no differences between brand switchers (M = 3.04, SD = 2.97) and generic switchers (M = 3.46, SD = 3.09) in efficacy ratings, t(299) = -1.17, p = .244, 95% CI - 1.14 to 0.29. The factors associated with efficacy ratings in the brand and generic switch groups were investigated. The regression model was significant for the brand switch group, F(10, 172) = 3.72, p < .001, $R^2 = .18$, and the generic switch groups, F(10, 84) = 5.07, p < .001, $R^2 = .38$. For both the brand and generic switch groups, the only variables that were significant predictors of new generic efficacy ratings was the pharmaceutical trust score and number of side effects reported (see table 3). Regardless of whether participants were switching from a branded medicine or a generic, a greater degree of trust in pharmaceutical agencies and fewer side effects reported were associated with a greater perceived efficacy of the new generic venlafaxine.

 Table 3 Factors associated with the efficacy ratings of the new generic medicine for brand switchers and generic switchers

	Brand Switchers			Generic Switchers			ners
В	β	p	95% CI for B	В	β	p	95% CI for B
-0.01	03	.656	-0.04, 0.03	0.02	.07	.457	-0.03, 0.06
0.53	.07	.304	-0.48, 1.54	-0.98	12	.187	-2.44, 0.48
-0.78	13	.079	-1.66, 0.09	-0.58	09	.339	-1.77, 0.62
-1.16	13	.086	-2.49, 0.17	0.03	.00	.966	-1.44, 1.51
-0.16	09	.245	-0.42, 0.11	-0.07	04	.677	-0.38, 0.25
0.16	.13	.083	-0.02, 0.34	0.02	01	.891	-0.25, 0.29
0.02	.03	.679	-0.07, 0.10	-0.03	04	.682	-0.15, 0.10
0.09	.26	<.001	0.04, 0.13	0.18	.45	<.001	0.11, 0.24
-0.02	01	.854	-0.18, 0.15	-0.01	01	.959	-0.22, 0.21
-0.17	24	.002	-0.28, -0.07	-0.27	33	<.001	-0.42, -0.13
	B -0.01 0.53 -0.78 -1.16 -0.16 0.16 0.02 0.09 -0.02 -0.02 -0.17	Bra β -0.01 03 0.53 .07 -0.78 13 -1.16 13 -0.16 .09 0.16 .13 0.02 .03 0.09 .26 -0.02 01 -0.17 24	B β p -0.01 03 .656 0.53 .07 .304 -0.78 13 .079 -1.16 13 .086 -0.16 .09 .245 0.16 .13 .083 0.02 .03 .679 0.09 .26 <.001	$\begin{tabular}{ c c c c c } \hline B & \beta & p & 95\% \ Cl \ for \ B \\ \hline 0.01 &03 & .656 & -0.04, \ 0.03 \\ \hline 0.53 & .07 & .304 & -0.48, \ 1.54 \\ \hline -0.78 &13 & .079 & -1.66, \ 0.09 \\ \hline -1.16 &13 & .086 & -2.49, \ 0.17 \\ \hline -0.16 &09 & .245 & -0.42, \ 0.11 \\ \hline 0.16 & .13 & .083 & -0.02, \ 0.34 \\ \hline 0.02 & .03 & .679 & -0.07, \ 0.10 \\ \hline 0.09 & .26 & <.001 & 0.04, \ 0.13 \\ \hline -0.02 &01 & .854 & -0.18, \ 0.15 \\ \hline -0.17 &24 & .002 & -0.28, \ -0.07 \\ \hline \end{tabular}$	B β p 95% Cl for B B -0.01 03 .656 -0.04, 0.03 0.02 0.53 .07 .304 -0.48, 1.54 -0.98 -0.78 13 .079 -1.66, 0.09 -0.58 -1.16 13 .086 -2.49, 0.17 0.03 -0.16 09 .245 -0.42, 0.11 -0.07 0.16 .13 .083 -0.02, 0.34 0.02 0.02 .03 .679 -0.07, 0.10 -0.03 0.09 .26 <.001	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Brand Switchers Generic Switch B β p 95% Cl for B B β p -0.01 03 .656 -0.04, 0.03 0.02 .07 .457 0.53 .07 .304 -0.48, 1.54 -0.98 12 .187 -0.78 13 .079 -1.66, 0.09 -0.58 09 .339 -1.16 13 .086 -2.49, 0.17 0.03 .00 .966 -0.16 09 .245 -0.42, 0.11 -0.07 04 .677 0.16 .13 .083 -0.02, 0.34 0.02 01 .891 0.02 .03 .679 -0.07, 0.10 -0.03 04 .682 0.09 .26 <.001

Side effect reports from the new generic

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

95% CI for B

-0.05, 0.07

-2.99, 1.06

-2.68, 0.60

-3.24, 0.79

-0.37, 0.50

-0.24, 0.51

-0.79, -0.24

-0.14, 0.20

-0.04, 0.17

-0.13.0.46

Generic Switchers

р

.671

.347

.210

.229

.766

.461

<.001

.718

.245

.282

ß

.04

-.10

-.13

-.12

.03

.08

-.42

.04

.13

.12

В

0.01

-0.96

-1.04

-1.23

0.07

0.13

-0.52

0.03

0.06

0.16

1 2 There was no significant difference in the brand group (M = 4.43, SD = 4.07) and generic 3 4 group (M = 4.85, SD = 3.91) in reported side effects following the switch to the new generic, 5 6 t(308) = -0.86, p = .392, 95% CI -1.36 to 0.54. An analysis of the factors associated with 7 8 greater side effect reporting for brand switchers and generic switchers was conducted and is 9 10 summarised in Table 4. The regression model of the brand switchers was significant, F(10, 10)11 12 $(172) = 3.61, p < .001, R^2 = .17$. Age, gender, education level, duration of time on the old 13 14 brand and perceived efficacy of the new generic were significantly associated with side effect 15 16 reporting. The analysis shows that brand switchers who were older, female, had an 17 18 education level below a university degree, had taken Efexor for a longer period of time and 19 20 had a lower perceived efficacy of the new generic reported a greater number of side effects 21 22 from the new generic medication. 23 24 The regression model for the generic switchers was also significant F(10, 84) = 2.13, 25 26 p = .031, $R^2 = .20$. However, the only significant predictor of side effects for this group was 27 28 perceived efficacy of the new generic. Generic switchers who had a lower perceived efficacy 29 30 of the new generic reported more side effects following the switch to the new generic. 31 32 33 34 35 36 Brand Switchers 37 В β 95% CI for B р Variable 38 .18 0.06 .017 0.01, 0.10 Age 39 Gender 1.41 .047 0.02, 2.79 .14 40 41 -.20 -2.81, -0.42 Education level -1.61 .008 42 Ethnicity -0.39 -.03 .680 -2.23, 1.46 43 Time on previous brand -0.50 -.20 .007 -0.86, -0.14 44 45 Perceived efficacy of old brand 0.21 .12 .102 -0.04, 0.46 46 -0.33 -.24 .002 -0.53, -0.13 Perceived efficacy of new generic 47 Perceived sensitivity to medicines -0.04 -.05 .486 -0.16, 0.08 48 Trust in pharmaceutical agencies -0.01 -.02 .760 -0.07, 0.06 49 50 Look up medicine information on internet -0.05 -.03 664 -0.28, 0.18 51

Table 4 Factors associated with side effect reporting for brand switchers and generic switchers

DISCUSSION

Key findings

59 60

52 53

54 55

56 57 58

BMJ Open

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In a sample of patients switched to a new generic version of venlafaxine the study found that preference for branded medication was associated with older age, being on the branded venlafaxine medication prior to the switch and a greater perceived sensitivity to medicines. A greater proportion of patients originally prescribed branded venlafaxine expected branded medicines to be more effective, safe and have fewer side effects than generics, compared to patients taking the generic who were more likely to perceive branded and generic medicines as equivalent. For both patient groups, those switching from the branded medication and those switching from a generic, a greater degree of trust in pharmaceutical agencies and less side effects reported were associated with a higher perceived efficacy of the new generic venlafaxine. For those switching from the branded drug for a longer time and having a lower perceived efficacy of the new generic was associated with reporting a greater number of side effects from the new generic medication. For those patients already on a generic, only a lower perceived efficacy of the new drug was associated with side effect reporting.

Implications

Switches from originator branded medicines to their generic counterparts provide an economic choice for health funders by enabling more patients to be treated through costsavings. Negative perceptions of generics can cause increased side effects and perceptions of lower efficacy, which may result in non-adherence and low persistence with the new drug and reduce the potential economic benefits of a switch. This study shows that trust in pharmaceutical agencies, including drug companies and regulators, is a key factor in patients' beliefs in the efficacy of the new generic medicine.

Another important finding of the study is the close reciprocal relationship between perceived drug efficacy and reported side effects. The presence of increased side effects are associated with a perception that the drug does not work as well and conversely, low efficacy beliefs are associated with greater reporting of side effects. This is consistent with a recent study that showed when side effects are modelled by another person receiving the same

medication (study confederate), this can influence not only reported side effects in the individual viewing the person but also reduce the effectiveness of the drug.[17]

The study also highlights the fact that patients who switch from a branded medicine and those who switch from a generic are likely to have different concerns. Patients already on a generic medicine tend to have a more favourable perception of generics compared to those taking a branded medicine and the factors that influence side effect reports following a medicine brand switch are different for brand switchers compared to generic switchers. People switching from branded medicines are likely to have more difficulties and interventions focused on building trust in pharmaceutical agencies around the switch are likely to have positive effects in influencing the perceived efficacy of the new drug and subsequent side effects. Advertising or education campaigns could aim to build trust around these pharmaceutical monitoring agencies. This could include explaining the level of testing required to establish drug equivalency and the monitoring of that does occur by drug agencies. There may also be an opportunity for intervention by their dispensing pharmacist with patients switching from a branded to generic formulation to reassure patients about these concerns.

Strengths and limitations

One of the strengths of the study was that it included patients who were switched from branded originator medication as well as patients on a generic. To our knowledge this is the first time a study has looked at these groups in the same switch to a generic to examine factors related to side effect reporting and efficacy perceptions. Previous research investigating perceptions and responses to medicine change has previously used placebo tablets and non-patient participants.[4,18] The fact that the sample was recruited from the Pharmac venlafaxine brand change webpage means these patients are likely to be more typical of patients who have concern and difficulties managing a generic switch. A weakness of the study was that patients were not randomly sampled and whether respondents were actually taking venlafaxine or experiencing the reported side effects could not be independently corroborated.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Conclusions

These results suggest that in a switch to a generic drug different factors are associated with preference for branded medicine, side effect reporting and perceived efficacy of the new drug in patients switching from a branded medicine and those already taking a generic. When switching to new generic there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust through an explanation of equivalence testing and monitoring could impact on efficacy beliefs, reduce nocebo effects and later non-adherence following a generic switch. Site.

rez oni

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: We have read and understood BMJ policy on declaration of interest and declare the following: KM declares no conflict of interest. KP has previously received research funding from Pharmac, the New Zealand Government's Pharmaceutical Management Agency.

Licence. The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and to exploit all subsidiary rights, as set out in our licence (bmj.com/advice/copyright.shtml).

Data sharing statement No additional data available.

Patient consent: Obtained

Ethics approval University of Auckland Human Participants Ethics Committee (ref. 018622).

REFERENCES

1. Colgan S, Faasse K, Martin LR, *et al.* Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. *BMJ Open* 2015;5:e008915.

2. Figueiras MJ, Cortes MA, Marcelino D, *et al.* Lay views about medicines: the influence of the illness label for the use of generic versus brand. *Psychol Health* 2010;25:1121-1128.

3. Pechlivanoglou P, Jan van der Veen W, Bos JH, *et al.* Analyzing generic and branded substitution patterns in the Netherlands using prescription data. *BMC Health Serv Res* 2011;11:89-98.

4. Faasse K, Cundy T, Gamble G, *et al*. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. *Psychosom Med* 2013;75:90-96.

5. Rathe J, Andersen M, Jarbøl DE, *et al.* Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study. *PLoS One* 2015;10:e0119688.

6. Weissenfeld J, Stock S, Lüngen M, *et al.* The nocebo effect: a reason for patients' non-adherence to generic substitution? *Die Pharmazie-An International Journal of Pharmaceutical Sciences* 2010;65:451-456.

7. Zeidan B, Anderson K, Peiris L, *et al.* The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients. *The Breast* 2016;29:62-67.

8 Desai RJ, Sarpatwari A, Dejene S, *et al.* Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. *BMJ* 2018;361:k1180.

9. Faasse K, Grey A, Horne R, *et al.* High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information seeking about medication. *Pharmacoepidemiol Drug Saf* 2015;24:592-599.

10. Balasopoulos T, Charonis A, Athanasakis K, *et al*. Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions. *Health Policy* 2017;121:265-272.

11. Webster RK, Weinman J, Rubin GJ. Medicine related beliefs predict attribution of symptoms to a sham medicine: a prospective study. *Br J Health Psychol* 2018.

12. Henry D. Patients say generic Pharmac-funded version of antidepressant venlafaxine left them depressed, anxious. *The New Zealand Herald* 2018 Feb. http://www.nzherald.co.nz/ (accessed 17 Apr 2018).

13. Maude S. Anti-depressant swap: Sufferers claim generic drug is harming their condition. *Stuff* 2018 Feb. https://www.stuff.co.nz (accessed 17 Apr 2018).

14. Petrie KJ, Faasse K, Crichton F, *et al.* How common are symptoms? Evidence from a New Zealand national telephone survey. *BMJ Open* 2014;4:005374.

15. Horne R, Faasse K, Cooper V, *et al*. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. *Br J Health Psychol* 2013;18:18-30.

16. Petrie KJ, Moss-Morris R, Grey C, *et al.* The relationship of negative affect and perceived sensitivity to symptom reporting following vaccination. *Br J Health Psychol* 2014;9:101-111.

17. Faasse K, Grey A, Jordan R, *et al.* Seeing is believing: impact of social modelling on placebo and nocebo responding. *Health Psychol* 2015;34:880-885.

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

18. Faasse K, Martin LR, Grey A, et al. Impact of brand or generic labeling on medication effectiveness and side effects. Health Psychol 2016;35:187-190.

<text>



 BMJ Open

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies				
Section/Topic	ltem #	Recommendation	Reported on page #	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	5	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7	
Bias	9	Describe any efforts to address potential sources of bias	8	
Study size	10	Explain how the study size was arrived at	5	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8	
		(b) Describe any methods used to examine subgroups and interactions	7-8	
		(c) Explain how missing data were addressed	NA	
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA	
		(e) Describe any sensitivity analyses	NA	
Results				

BMJ Open: first published as 10.1136/bmjopen-2018-023667 on 18 October 2018. Downloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright_h/instlictionstrates/selated fortext.and/data/mitringr/Ab training.and/similar technologies.

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,	8
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	10-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	11, 12
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	NA
		which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

AT-LZA Townloaded from http://bmjopen.bmj.com/ on May 19, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright,/insluidipplofnes.gejated fotext.andicata/mining text.andionalad text.andiones.